Honokiol and Its Emerging Role in Breast Cancer Therapy

Area of Science:

• Oncology
• Pharmacology
• Natural Products

Background:

• Honokiol (HNK), derived from Magnolia species, is a bioactive compound with demonstrated therapeutic potential in breast cancer (BrCa).
• Preclinical studies indicate HNK's ability to target essential oncogenic pathways, reduce oxidative stress, inflammation, metabolic reprogramming, and cancer stemness.

Purpose of the Study:

• To review the mechanistic, preclinical, and emerging clinical data on Honokiol for breast cancer treatment.
• To highlight challenges and future trends for incorporating HNK into multimodal breast cancer therapy.

Main Methods:

• Review of in vitro and in vivo studies on Honokiol's effects on breast cancer.
• Analysis of HNK's synergistic activity with various breast cancer therapies.
• Evaluation of nanotechnological delivery systems for HNK.

Main Results:

• HNK inhibits critical oncogenic pathways and exhibits anti-inflammatory and anti-oxidative effects.
• HNK shows synergistic effects with chemotherapy, endocrine therapy, targeted therapy, and immune checkpoint inhibitors across diverse breast cancer subtypes.
• Nanodelivery systems improve HNK's solubility, bioavailability, and tumor accumulation.

Conclusions:

• Honokiol is a promising multifunctional agent for breast cancer, demonstrating broad-spectrum efficacy in preclinical models.
• Further clinical investigation is required to establish the safety and efficacy of HNK in human breast cancer patients.
• Optimized delivery systems and multimodal therapeutic strategies are key for advancing HNK in clinical practice.